How tenofovir disoproxil fumarate can impact on solubility and dissolution rate of efavirenz?

被引:15
|
作者
Bazzo, Giovana Carolina [1 ]
Mostafa, Dina [1 ]
Franca, Maria Terezinha [1 ]
Pezzini, Bianca Ramos [1 ]
Stulzer, Hellen Karine [1 ]
机构
[1] Univ Fed Santa Catarina, Programa Posgrad Farm, Campus Trindade, BR-88040970 Florianopolis, SC, Brazil
关键词
Efavirenz; Tenofovir disoproxil fumarate; Solubility; Dissolution; Eutectic mixture; DRUG-DELIVERY SYSTEM; SOLID FORMS; ENHANCEMENT; CYCLODEXTRIN; MECHANISMS; BEHAVIOR; DESIGN;
D O I
10.1016/j.ijpharm.2019.118597
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Efavirenz (EFZ) and tenofovir disoproxil fumarate (TDF) can be used simultaneously in the treatment of human immunodeficiency virus type1 infection. In this work the impact of TDF, a hydrophilic drug, on the solubility and dissolution rate of EFZ, a poorly water-soluble drug, was evaluated. EFZ/TDF binary mixtures in different molar ratios were prepared. Differential scanning calorimetry (DSC) results indicate the formation of a eutectic mixture, the molar ratio of 65/35 being the eutectic point. It was observed an increase in the EFZ solubility in water and acidic conditions (0.1 N HCl and biorelevant medium), in the presence of TDF. On the other hand, there was a decreasing on EFZ solubility in phosphate buffer pH 6.8, probably influenced by the lower solubility of TDF in this medium. The high solubility of TDF in water and acidic medium may have contributed to improve the solubility of EFZ, as well as the formation of a eutectic mixture, supported by X-ray powder diffraction (XRPD) and Fourier Transform infrared spectroscopy (FTIR) analyses. However, TDF solubility and dissolution rate was not significantly influenced by the presence of EFZ.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results
    Zolopa, Andrew
    Sax, Paul E.
    DeJesus, Edwin
    Mills, Anthony
    Cohen, Calvin
    Wohl, David
    Gallant, Joel E.
    Liu, Hui C.
    Plummer, Andrew
    White, Kirsten L.
    Cheng, Andrew K.
    Rhee, Martin S.
    Szwarcberg, Javier
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 63 (01) : 96 - 100
  • [22] Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection
    Bedimo, Roger
    Rosenblatt, Lisa
    Myers, Joel
    HIV CLINICAL TRIALS, 2016, 17 (06): : 246 - 266
  • [23] Development and Validation of Ultra Performance Liquid Chromatographic Method for the Simultaneous Estimation of Lamivudine, Tenofovir Disoproxil Fumarate, Doravirine and Efavirenz in Bulk and Pharmaceutical Formulations
    Chengalva, Prasanthi
    Kuchana, Madhavi
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 82 (06) : 1006 - 1014
  • [24] Preparation and characterization of Efavirenz nanosuspension with the application of enhanced solubility and dissolution rate
    Kommavarapu, Pavan
    Maruthapillai, Arthanareeswari
    Palanisamy, Kamaraj
    HIV & AIDS REVIEW, 2016, 15 (04): : 170 - 176
  • [25] Simultaneous Estimation and Validation of Tenofovir Disoproxil Fumarate, Emtricitabine and Efavirenz by RP-HPLC Method in Combined Tablet Dosage Form
    Rezaei, Mehdi
    Ramazani, Ali
    Hokmabadi, Fahimeh
    CURRENT PHARMACEUTICAL ANALYSIS, 2019, 15 (06) : 561 - 567
  • [26] Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients
    Droste, JAH
    Kearney, BP
    Hekster, YA
    Burger, DM
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (01) : 37 - 43
  • [27] Prevalence and Associated Factors of Neurocognitive Impairment in HIV-Positive Patients on Effective Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Treatment
    Giancola, Maria Letizia
    Balestra, Pietro
    Ammassari, Adriana
    Ricottini, Martina
    Lorenzini, Patrizia
    Angeletti, Claudio
    Bellagamba, Rita
    Tommasi, Chiara
    Tempestilli, Massimo
    Zaccarelli, Mauro
    Pinnetti, Carmela
    Gallo, Anna Loredana
    Antinori, Andrea
    Narciso, Pasquale
    Nicastri, Emanuele
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 (11) : 907 - 908
  • [28] Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial
    Orkin, Chloe
    Squires, Kathleen E.
    Molina, Jean-Michel
    Sax, Paul E.
    Wong, Wing-Wai
    Sussmann, Otto
    Kaplan, Richard
    Lupinacci, Lisa
    Rodgers, Anthony
    Xu, Xia
    Lin, Gina
    Kumar, Sushma
    Sklar, Peter
    Nguyen, Bach-Yen
    Hanna, George J.
    Hwang, Carey
    Martin, Elizabeth A.
    CLINICAL INFECTIOUS DISEASES, 2019, 68 (04) : 535 - 544
  • [29] Metabolic, Mitochondrial, and Inflammatory Effects of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate in Asymptomatic Antiretroviral-Naïve People with HIV
    Barroso, Sergio
    Guitart-Mampel, Mariona
    Garcia-Garcia, Francesc Josep
    Canto-Santos, Judith
    Valls-Roca, Laura
    Andujar-Sanchez, Felix
    Vilaseca-Capel, Adria
    Tobias, Ester
    Arias-Dimas, Angela
    Quesada-Lopez, Tania
    Artuch, Rafael
    Villarroya, Francesc
    Giralt, Marta
    Martinez, Esteban
    Lozano, Ester
    Garrabou, Gloria
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (15)
  • [30] Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (Atripla®) A Review of its Use in the Management of HIV Infection
    Deeks, Emma D.
    Perry, Caroline M.
    DRUGS, 2010, 70 (17) : 2315 - 2338